Alnylam Sets 2030 GHG Reduction Targets, Expands Patient Access Initiatives

Event summary

  • Alnylam published its 2025 Corporate Responsibility Report, outlining a 2030 greenhouse gas (GHG) emissions reduction framework for Scope 1 and Scope 2 emissions.
  • The company launched a new Patient Advisory Council and expanded its Case Management and Access & Reimbursement teams.
  • Alnylam committed $2 million over two years to support frontline Care Navigators in underserved Boston communities through its Alnylam Challengers philanthropy program.
  • The report highlighted case studies demonstrating the strategic value of investments in AI, manufacturing, clinical trials, and employee resource networks.

The big picture

Alnylam's 2025 Corporate Responsibility Report underscores the growing emphasis on ESG commitments within the biopharmaceutical sector. The company's strategic focus on sustainability, patient access, and community health aligns with broader industry trends toward socially responsible business practices. With six approved medicines and a robust pipeline, Alnylam is positioning itself as a leader in both therapeutic innovation and corporate governance.

What we're watching

Sustainability Execution
Whether Alnylam can achieve its 2030 GHG emissions reduction targets amid evolving regulatory landscapes.
Patient Access Impact
How the expansion of patient access initiatives will affect market penetration and regulatory compliance.
Philanthropic ROI
The long-term impact of the $2 million investment in Care Navigators on community health outcomes and corporate reputation.